Management strategies of academic pigmented lesion clinic directors in the United States
To the Editor: To our knowledge, there have been no previous surveys specifically targeting pigmented lesion clinic (PLC) directors in the United States, and little is known regarding their management strategies. These individuals were surveyed electronically during 2015-2016 via REDCap (Research Electronic Data Capture) 1 regarding their methods of biopsy, preferences for pathologic grading of nevus atypia, and management of various scenarios. The University of Pennsylvania Institutional Review Board approved this study. Statistical analysis was performed using Stata 13.1 (StataCorp LLC, College Station, TX). Eligible participants, defined as PLC directors practicing in the United States, were identified from prior lists of PLC directors and by calling each dermatology residency program. The final list was comprehensive, with all contacted physicians and residency programs responding as to eligibility. Forty eligible PLC directors were identified, and 38 (95%) participated.
Biopsy techniques and pathology reporting preferences are in Table I . All respondents indicated they perform diagnostic biopsies intending to remove the entire pigmented lesion, with roughly equal preference for shave/saucerization removal (55%) versus full-thickness ( punch, elliptical) excision (45%). The vast majority (92%) use pathologists who grade nevus atypia and dysplasia on a mild/moderate/severe scale, and most (74%) preferred such grading.
Recommendations after initial biopsy are in Table II . For scenarios in which the diagnostic biopsy removed the clinically visible lesion but there were positive microscopic margins, there was near universal agreement for 3 scenarios: 1) nevi with mild dysplasia do not require re-excision; 2) nevi with severe dysplasia require an additional procedure, although recommendations for clinical margins varied widely; and 3) atypical spitz nevi in an adult also require an additional procedure, but again with varying margin recommendations. Recommendations for nevi with moderate atypia or classic spitz nevi in an adult varied widely, with no consensus. Prior surveys of general dermatologists found even broader ranges of management for dysplastic nevi. 2, 3 For nevi with severe atypia and atypical spitz nevi in adults with negative microscopic margins, there was no management consensus.
Eight (28%) participants recommended a sentinel node biopsy for at least some adults with an atypical spitz nevus with negative histologic margins. All eight respondents provided unsolicited information describing factors in decision-making, including degree of histologic atypia (7/8); clinical atypia (2/8); immunohistochemical staining patterns (1/8), and either comparative genomic hybridization or fluorescence in-situ hybridization (4/8).
Fourteen respondents (36%) had a patient who developed melanoma at the site of an incompletely excised nevus or dysplastic nevus (of any grade); respondents with greater than the median (15 years) duration of pigmented lesion specialization were significantly more likely to have observed this scenario (odds ratio 10, P ¼ .004). Some respondents who had seen this phenomenon elaborated further. In some cases, new pigmentation occurred in a scar with no prior pigmentation, while others described partial sampling of the original lesion. Review of the original diagnostic slides sometimes upheld and sometimes altered the original benign diagnosis.
PLC directors play an important role in the management of patients with melanocytic lesions. Areas of consensus among directors help in establishing guidelines for care. Other areas with no consensus are ripe for further study. To the Editor: The Vitiligo Extent Score (VES) is a reliable and valid instrument to assess vitiligo extent at a specific time point (ie, static assessment), but its ability to detect changes (ie, dynamic assessment) is still unclear.
1 Because vitiligo experts' main concern related to the VES was the absence of an integrated perifollicular repigmentation pattern, the original instrument was modified (ie, VESplus) to optimize precision in case of treatment evaluation (Fig 1; added perifollicular scale in the VESplus). 2 In a recent, related research letter, we confirmed the validity and reliability of this modified tool (VESplus). 3 In this study, we evaluated the responsiveness of the VESplus and its reliability to detect changes compared with the VES. In addition, the possible use for both global (ie, total body) and regional assessment of repigmentation (ie, all locations separately) were investigated.
VES and VESplus were independently performed on paired pictures of 2 time points of vitiligo patients on cream ( group 1, n ¼ 28; 3 raters) or ultraviolet B therapy ( group 2, n ¼ 29; 2 raters). Responsiveness was evaluated by 3 predefined hypotheses (ie, construct approach). 4 If all hypotheses were in accordance with the results, it was assumed that there was evidence for adequate responsiveness. The 3 hypotheses defined were 1) percentage repigmentation after ultraviolet B would be $ 10% higher (on average) compared with topical treatments; 2) in patients with improvement, lesions on the face would have $10% higher repigmentation than lesions on the hands; and 3) there would be a coefficient of rank correlation $0.5 between the method and global assessment score. The global assessment score on a 5-point scale (clear worsening [e2] to clear improvement [12] ) was performed by an expert (Dr Wolkerstorfer). Approval by ethics committees was obtained.
Inter-and intrarater reliability (interval between ratings 6 2 weeks or more) of VESplus and VES were investigated on the observed differences between the
